According to the latest data from the Hong Kong Stock Exchange, on January 2nd, JPMorgan increased its holding in Innovent Biologics (01801) by 3,173,036 shares. The transaction was executed at a price of HK$78.4477 per share, amounting to a total consideration of approximately HK$249 million. Following this acquisition, JPMorgan's latest shareholding quantity stands at about 88.9573 million shares, representing a 5.16% stake in the company.